Sara Al-Zubeidi
Director, Commercial Strategy Consulting Global Pricing and Market Access
Sara Al-Zubeidi is a Director with Clarivate based in London. Sara has 7+ years commercial strategy consulting experience in life sciences, specializing in global pricing and market access.
Sara leads teams for global P&MA engagements on behalf of pharmaceutical and biotechnology companies. Areas of expertise include pricing and access strategy, evidence generation for HTA submission, innovative agreement strategy, HTA landscape analysis, analogue assessments, value proposition/story development and payer objection handling/negotiation tactics. She also has extensive experience in commercial opportunity assessments, including indication and opportunity prioritization and patient flow assessments. Sara has deep expertise across a wide span of therapeutic areas with oncology, orphan/rare diseases, cardiology, renal and metabolic diseases as specialist areas of interest.
Prior to joining consulting, Sara worked in business development specifically for HEOR and Evidence Strategy teams.
Sara has a Master’s degree in Pharmacogenetics and Stratified Medicine at University College of London (UCL) and a BSc (Hons) in Medical Genetics from Queen Mary University of London.
Latest news
Clarivate Selected by University of Texas at Dallas Libraries to Provide Alma Specto
Alma Specto, an AI-native digital collection and exhibition platform offers UT Dallas Libraries a scalable, flexible and future-ready solution, expanding the reach of its Special Collections to new audiences London,…
Clarivate Reveals the AI50 – the Organizations Leading Artificial Intelligence Invention
London, U.K. March, 26, 2026. Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the Clarivate AI50, a new data-driven benchmark of organizations demonstrating exceptional leadership in…
